BCL2 and central nervous system cancer: Nonetheless, we utilized longitudinal bioluminescence imaging to monitor any changes in the progression of U251.eGFP.ffluc glioma orthotopic xenografts if treated with either parental or Bcl-2-expressing CD-NSCs, followed by 5 consecutive days of prodrug administration (Figures 4(b) and 4(c)).